Skip Navigation
Explore our COVID-19 Resources and Updates
CHS blue logo square
Home > Our Work > All Publications > 2010


Our publications keep professionals working across the public, private, and academic sectors informed on the most important developments and issues in health security and biosecurity.

Find an article or report by keywords:

Find an article or report or see all by area, author, or year:


Clostridium difficile: Moving Beyond Antimicrobial Therapy

Amesh A. Adalja, J. A. Kellum
Date posted:
January 21, 2010
Publication type:

Crit Care 2010;14(5):320

Society of Critical Care Medicine
See also:

Infection with Clostridium difficile places a significant burden on healthcare facilities. C. difficile has been shown to substantially increase hospital costs, hospital length of stay, and contribute to mortality [1,2]. One of the major factors hindering successful treatment of C. difficile-associated disease is the high rate of recurrence. Risk factors for recurrence include continued antibiotic use, antacid use, and older age [3]. Anecdotal evidence supports the use of several different modalities, such as tapering doses of vancomycin, rifaxamin, and fecal transplant. Yet, to date none of these therapies have been shown to be effective. Myriad risk factors for C. difficile infection coalesce in intensive care units, making it a highly relevant condition for intensivists. 



Our Mission

To protect people’s health from epidemics and disasters and ensure that communities are resilient to major challenges.